September 6, 2026
SOHO Insider Hem/Onc Library Lymphoma Indolent B-Cell Lymphomas

Indolent B-Cell Lymphomas

Time for Phase 2. Hand holds a cube with number '2'. Word 'Phase 2'. Beautiful black background. Business concept. Copy space.
Lymphoma Indolent B-Cell Lymphomas

Atezolizumab plus obinutuzumab, radiotherapy combination safe, effective against FL

SOHO 2026 Acute Lymphoblastic Leukemia Acute Myeloid Leukemia Chronic Lymphocytic Leukemia Chronic Myeloid Leukemia Aggressive B-Cell Lymphomas Indolent B-Cell Lymphomas Mantle Cell Lymphoma T-Cell Lymphoma Multiple Myeloma Myelodysplastic Syndromes Myeloproliferative Neoplasms Society Updates

Registration now open for SOHO 2026

FDA Green light
Lymphoma Indolent B-Cell Lymphomas News

Brazil regulatory agency approves tafasitamab combo in R/R follicular lymphoma

Silver,Spring,,Md,,Usa,-,June,25,,2022:,The,Fda
Cellular Therapy Lymphoma Indolent B-Cell Lymphomas News

FDA approves subcutaneous mosunetuzumab in relapsed or refractory follicular lymphoma

Chinese flag
Leukemia Chronic Lymphocytic Leukemia Lymphoma Indolent B-Cell Lymphomas News

China NMPA approves pirtobrutinib in relapsed/refractory CLL/SLL

SOHO UK Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas Indolent B-Cell Lymphomas News

Prof. Peter Johnson, CBE, on accelerating cancer trials in the UK

Discontinuation
Cellular Therapy Lymphoma Indolent B-Cell Lymphomas News

Liso-cel shows good 3-year response, safety results in patients with R/R follicular lymphoma

FDA
Leukemia Chronic Lymphocytic Leukemia Lymphoma Indolent B-Cell Lymphomas News

FDA approves acalabrutinib plus venetoclax for CLL, SLL

Loretta Nastoupil
Lymphoma Roundtable Lymphoma Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

CELMoDs in the second-line setting in follicular lymphoma

Jason Westin, MD
Lymphoma Roundtable ASH 2025 Cellular Therapy Lymphoma Aggressive B-Cell Lymphomas Indolent B-Cell Lymphomas Roundtable Discussions Video Interviews

What are the therapeutic combinations in large cell lymphoma?